about
sameAs
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in MiceSimple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry.Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers.A case of rectal cancer arising from long-standing prolapsed mucosa of the rectum.Frequency and risk factors for rebleeding events in patients with small bowel angioectasia.LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.[Gut microbiota and NASH].Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distributionMetformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trialComparative Study of 2 Different Questionnaires in Japanese Patients: The Quality of Life and Utility Evaluation Survey Technology Questionnaire (QUEST) Versus the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease Questionnaire (FSCharacteristics of the small bowel lesions detected by capsule endoscopy in patients with chronic kidney disease.Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.Emerging drugs for non-alcoholic steatohepatitis.Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis.Identification of core gene networks and hub genes associated with progression of non-alcoholic fatty liver disease by RNA sequencing.Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study.Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis.Identification of the genomic region under epigenetic regulation during non-alcoholic fatty liver disease progression.Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy.Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental factorsDoes postprandial itopride intake affect the rate of gastric emptying? A crossover study using the continuous real time 13C breath test (BreathID system)Acute obstructive cholangitis caused by an enterolith in a duodenal diverticulumAssessment of small bowel motility in patients with chronic intestinal pseudo-obstruction using cine-MRIInsulin resistance correlated with the severity of liver histology in Japanese NAFLD patients: a multicenter retrospective studyEfficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study designEffect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)
P50
Q28552063-026CBFFC-FC8B-40AE-955E-EBAC568927B8Q30433234-3122E9B0-743F-4C9D-8584-C62DD69F111AQ30821159-E8DFB704-81EC-4E8B-BA92-E90F9B8E1D40Q33565654-DC52F1E1-1048-4D80-B814-A0BFD00A614FQ34229098-D6CEBFEF-00DC-491A-BC8B-AD794C979313Q34676797-AAD839A4-572E-4504-9779-593D0A5F84C0Q34776084-2C0A94CD-BA87-488B-AE85-BB1FB8CB4D06Q35293633-B51DA39B-7513-4EFA-B4E9-7F8D1972DF98Q35832543-17C5565F-643B-49D5-9894-22014A2B4E20Q35871671-24313493-036E-4326-BE3F-F3BACEF816B5Q35963205-E09F614F-F1B0-46D6-918F-B70ECFB53437Q36542684-B6D41F2D-9DF0-4A67-8740-D58A493DF2ECQ37162982-B2919075-E910-4361-87A8-8DA078D688FCQ37375389-7A0F561E-4C2F-443D-8C30-D4A4C4E92D02Q37640263-0E007D96-1AC1-438E-AD13-89E2EDAB5BFDQ38121137-36412810-7C56-4391-BAFA-83631FA7116BQ38623028-84D7E8D4-81E4-4C6F-9090-A1E108A5B299Q38951594-C7DDD309-2F67-4888-B415-57DD8A9FDC51Q39944738-A48D8606-EAFD-44BD-8AD1-AA761AD469C7Q41042091-1A1AA1EB-572D-4598-9689-B2D1912A17AAQ41319267-820B757C-B08C-425D-87EC-8DFCE358A297Q44779119-F8F58AA4-A1C4-4783-8DD1-3001B97DD6BFQ47615586-340E28B8-E857-4CD8-917C-965980C79F9EQ48128861-75C6E377-5F1E-4B1D-AD69-5B92421326F2Q60507076-A0CB7462-8071-48BD-9A4E-4D932E0A56D2Q83923938-D9A4A418-F179-4A51-8245-3B81FFA7D092Q85037615-25133FC8-7CE3-4F3D-83ED-9E638C92CE95Q86430897-774F55F7-AB36-43B5-ACAB-6A29BC232165Q87385282-8845987D-2016-47FA-B7E4-7888775BACADQ88299486-77FAF131-394B-4B95-9EAB-60B1C4111ED9Q92760373-BD55C35C-9989-447D-B2AF-0DCFF36AAB54
P50
description
researcher ORCID ID = 0000-0002-5587-1386
@en
wetenschapper
@nl
name
Takaomi Kessoku
@ast
Takaomi Kessoku
@en
Takaomi Kessoku
@es
Takaomi Kessoku
@nl
type
label
Takaomi Kessoku
@ast
Takaomi Kessoku
@en
Takaomi Kessoku
@es
Takaomi Kessoku
@nl
prefLabel
Takaomi Kessoku
@ast
Takaomi Kessoku
@en
Takaomi Kessoku
@es
Takaomi Kessoku
@nl
P106
P31
P496
0000-0002-5587-1386